New drug trial targets Tough-to-Treat kidney disease
Disease control
Not yet recruiting
This is a first-in-human study to test the safety and initial effects of an experimental drug called YK012. It is for adults with a severe form of primary membranous nephropathy, a serious kidney disease, who have not responded to other available treatments. The main goal is to f…
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC